Tailored therapeutic approaches in acute myeloid leukaemia
- 27 Downloads
PURPOSE OF REVIEW: In recent years new molecular markers have emerged as significant prognostic parameters and as potential targets for molecularly targeted therapy in acute myeloid leukaemia (AML). Prognostic markers, however, cannot guide the decision for a specific treatment since they are associated with a differential outcome regardless of the given treatment. In contrast, predictive markers indicate a treatment benefit in patients that are characterized through these markers. Thus predictive markers can guide clinical decision-making. RECENT FINDINGS: In young adults mutations of the NPM1 (NPM1mut) gene in the absence of concurrent FLT3-ITD (FLT3-ITDneg) mutations have impressive prognostic and beyond prognostication also predictive properties. This NPM1mut/FLT3-ITDneg genotype predicts equivalent favourable outcome after intensive chemotherapy and allogeneic stem cell transplantation, whereas in the absence of this marker clinical outcome was significantly improved after an allogeneic transplantation. In addition, within a retrospective study performed in older adults the same genotype predicted a significantly improved outcome if all-trans retinoic acid was added to intensive chemotherapy. SUMMARY: The discovery of new prognostic and predictive markers has increased our understanding of leukaemogenesis thus leading to an improved prognostication. Furthermore, current clinical research focusing on the assessment of genotype-specific therapy may translate into an increase in the cure rate.
KeywordsAcute myeloid leukaemia ATRA NPM1 FLT3-ITD
Unable to display preview. Download preview PDF.
- Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program, 80–97. Review, 2004Google Scholar
- Byrd JC, Mrózek K, Dodge RK, et al. Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100: 4325–4336, 2002PubMedCrossRefGoogle Scholar
- Grisendi S, Mecucci C, Falini B, et al. Nucleophosmin and cancer. Nat Rev, 6: 493–505, 2006Google Scholar
- Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98: 1752–1759, 2001PubMedCrossRefGoogle Scholar
- Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplication. Blood, 111: 1552–1559, 2008PubMedCrossRefGoogle Scholar
- Schlenk RF, Döhner K, Kneba M, et al. Gene Mutations and Response to Treatment with All-Trans Retinoic Acid in Elderly Patients with Acute Myeloid Leukemia – Results from AMLSG Trial AML HD98B. Haematologica, 2008 Dec 4. [Epub ahead of print]Google Scholar
- Bornhäuser M, Illmer T, Schaich M, et al. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood, 109: 2264–2265, 2007. (Letter to the editor showing superior outcome of patients with FLT3-ITDpos AML after allogeneic or autologous SCT compared to chemotherapy, population of the original studies not stated, missing values not addressed, multivariable analysis not included.)PubMedCrossRefGoogle Scholar
- Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood, 106: 3658–3665, 2005PubMedCrossRefGoogle Scholar
- Arber DA, Vardiman JW, Brunning RD, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Fourth edition. WHO Press, Geneva, Switzerland, 2008; pp 120–122Google Scholar
- Stone R, Fischer T, Paquette R, et al. Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under Age 61. Blood, 108: 157 #abstract, 2006CrossRefGoogle Scholar